Opdivo

Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
CP WIre
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Flag link:
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Flag link:
In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type
In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type
Fierce Pharma
Merck
Keytruda
Opdivo
Bristol Myers Squibb
pleural mseothelioma
mesothelioma
clinical trials
Flag link:
Bristol Myers axes German launch of new cancer drug, citing pricing hurdles
Bristol Myers axes German launch of new cancer drug, citing pricing hurdles
Endpoints
Bristol Myers Squibb
Germany
Opdivo
Opdualag
Flag link:
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
BioPharma Dive
Big Pharma
patents
patent cliff
biosimilars
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Opdivo
Flag link:
Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial
Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial
Seeking Alpha
CompuGen
COM701
Bristol Myers Squibb
Opdivo
ovarian cancer
platinum-resistant ovarian cancer
Flag link:
Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?
Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?
Endpoints
Bristol Myers Squibb
Opdivo
melanoma
Merck
Keytruda
Flag link:
Bristol Myers' Opdivo win tees up showdown with Keytruda in earlier-stage melanoma
Bristol Myers' Opdivo win tees up showdown with Keytruda in earlier-stage melanoma
Fierce Pharma
Merck
Keytruda
Bristol Myers Squibb
Opdivo
melanoma
Flag link:
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
Fierce Pharma
ESMO
Roche
Bristol Myers Squibb
kidney cancer
Keytruda
Merck
Opdivo
Yervoy
Flag link:
Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?
Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?
Fierce Pharma
Exelixis
Cabometyx
kidney cancer
Opdivo
Yervoy
Bristol Myers Squibb
Flag link:
ASCO: Bristol Myers adds to debate with Opdivo's presurgery lung cancer performance
ASCO: Bristol Myers adds to debate with Opdivo's presurgery lung cancer performance
Fierce Pharma
ASCO 2022
Bristol Myers Squibb
lung cancer
Opdivo
Flag link:
The patent winter is coming
The patent winter is coming
EP Vantage
patents
biosimilars
patent cliff
Keytruda
Opdivo
Eliquis
Darzalex
Revlimid
Humira
Stelara
AbbVie
Merck
Bristol Myers Squibb
JNJ
Flag link:
Bristol needs to get fresh
Bristol needs to get fresh
EP Vantage
Bristol Myers Squibb
Opdivo
Flag link:
Bristol Myers scraps $2B Nektar partnership after trial failures
Bristol Myers scraps $2B Nektar partnership after trial failures
BioPharma Dive
Bristol Myers Squibb
Nektar Therapeutics
immunotherapy
Opdivo
kidney cancer
bladder cancer
Flag link:
What’s next for Bristol Myers' relatlimab?
What’s next for Bristol Myers' relatlimab?
EP Vantage
Bristol Myers Squibb
relatilimab
Opdivo
Opdualag
melanoma
Flag link:
BMS-Nektar's Opdivo combo fails phase 3 in upset to once-largest licensing deal in biotech history
BMS-Nektar's Opdivo combo fails phase 3 in upset to once-largest licensing deal in biotech history
Fierce Biotech
Bristol Myers Squibb
Opdivo
Nektar Therapeutics
bempegaldesleukin
clinical trials
Flag link:
FDA hands Bristol Myers a landmark approval in early-stage lung cancer after just five days
FDA hands Bristol Myers a landmark approval in early-stage lung cancer after just five days
Endpoints
FDA
Bristol Myers Squibb
Opdivo
early-stage lung cancer
Flag link:
BMS, Novartis, Akebia and more face FDA approval decisions soon, with big sales on the line
BMS, Novartis, Akebia and more face FDA approval decisions soon, with big sales on the line
Fierce Pharma
FDA
drug approvals
FibroGen
AstraZeneca
daprodustat
Bristol Myers Squibb
Opdivo
Roche
tiragolumab
Merck
favezelima
bInnovent
Eli Lilly
Akeso Biopharma
Sino Biopharmaceutical
Novartis
Ukoniq
TG Therapeutics
GW Pharmaceuticals
Marinus Pharmaceuticals
Flag link:
Bristol Myers' Opdivo steps in FDA fast lane for potential first-in-class nod in pre-surgery lung cancer
Bristol Myers' Opdivo steps in FDA fast lane for potential first-in-class nod in pre-surgery lung cancer
Fierce Pharma
Bristol Myers Squibb
FDA
Opdivo
priority review
non-small cell lung cancer
Flag link:
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
Fierce Pharma
JPMHC 2022
Bristol Myers Squibb
Revlimid
patent cliffs
Opdivo
Eliquis
Reblozyl
Breyanzi
Flag link:

Pages